ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,600.22
-0.92%
Dow Jones
41,911.71
-2.08%
Gold vs US Dollar
2,883.075
-0.97%
Brent Oil
69.04
-0.98%
Bitcoin
78,800.01
-2.21%
Pepperstone
Advertisement
Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. Tenaya Therapeutics Inc (TNYA)

  7. Tenaya Therapeutics Inc (TNYA) News

Tenaya Therapeutics (TNYA)

Tenaya Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:TNYA
DateTimeSourceHeadlineSymbolCompany
10/03/202520:19Edgar (US Regulatory)Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]NASDAQ:TNYATenaya Therapeutics Inc
10/03/202520:13Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
10/03/202520:05GlobeNewswire Inc.Tenaya Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
04/03/202521:28Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
04/03/202521:19Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
04/03/202504:19GlobeNewswire Inc.Tenaya Therapeutics Announces Pricing of Public OfferingNASDAQ:TNYATenaya Therapeutics Inc
03/03/202521:16Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:TNYATenaya Therapeutics Inc
03/03/202521:10GlobeNewswire Inc.Tenaya Therapeutics Announces Proposed Public OfferingNASDAQ:TNYATenaya Therapeutics Inc
03/03/202521:04Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:TNYATenaya Therapeutics Inc
03/03/202513:00GlobeNewswire Inc.Tenaya Therapeutics to Participate in Upcoming March Investor ConferencesNASDAQ:TNYATenaya Therapeutics Inc
08/02/202501:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
07/02/202521:58Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:TNYATenaya Therapeutics Inc
07/02/202521:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
05/02/202518:23Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:TNYATenaya Therapeutics Inc
03/02/202513:30GlobeNewswire Inc.Tenaya Therapeutics Receives $8 Million Clinical Grant from California Institute for Regenerative MedicineNASDAQ:TNYATenaya Therapeutics Inc
29/01/202501:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
28/01/202522:12Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
13/01/202514:16GlobeNewswire Inc.Tenaya Therapeutics Announces 2025 Strategic Priorities and Anticipated MilestonesNASDAQ:TNYATenaya Therapeutics Inc
17/12/202412:58Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
17/12/202412:24Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
17/12/202412:00GlobeNewswire Inc.Tenaya Therapeutics Reports Promising Early Data from MyPEAK™-1 Phase 1b/2 Clinical Trial of TN-201 for Treatment of MYBPC3-Associated Hypertrophic CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
16/12/202421:30GlobeNewswire Inc.Tenaya Therapeutics to Announce Initial Data from MyPEAK-1 Phase 1b/2 Clinical Trial of TN-201 Gene Therapy for MYBPC3-Associated Hypertrophic Cardiomyopathy on Tuesday, December 17, 2024NASDAQ:TNYATenaya Therapeutics Inc
25/11/202413:30GlobeNewswire Inc.Tenaya Therapeutics Doses First Patient in RIDGE™-1 Phase 1b Clinical Trial of TN-401 for the Treatment of PKP2-Associated Arrhythmogenic Right Ventricular CardiomyopathyNASDAQ:TNYATenaya Therapeutics Inc
19/11/202413:00GlobeNewswire Inc.Tenaya Therapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)NASDAQ:TNYATenaya Therapeutics Inc
19/11/202401:48Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
06/11/202421:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
06/11/202421:20Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:TNYATenaya Therapeutics Inc
06/11/202421:16Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:TNYATenaya Therapeutics Inc
06/11/202421:05GlobeNewswire Inc.Tenaya Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business UpdateNASDAQ:TNYATenaya Therapeutics Inc
22/10/202400:40Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:TNYATenaya Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:TNYA

Your Recent History

LSE
WG.
Wood Group (john)
LSE
TERN
Tern
LSE
BIRD
Blackbird
LSE
VAST
Vast Resources
LSE
POS
Plexus
LSE
TSLA
1x Tsla
LSE
VRS
Versarien
LSE
AAZ
Anglo Asian Mining
LSE
EEE
Empire Metals
LSE
SBTX
Skinbiotherapeutics
LSE
SYME
Supply@me Capital
LSE
AGR
Assura
LSE
UPS
LSE
NEXN
Nexxen
LSE
PXC
Phoenix Copper
LSE
THG
Thg
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2025 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads